Clinics and research in hepatology and gastroenterology最新文献

{"title":"Natalizumab-Induced Autoimmune Liver Injury.","authors":"Jeanete Sharay Rodriguez-Martinez, Nancy Haydee Serrano-Perez, Guillermo Espinosa-Zarazua, Jacqueline Cordova-Gallardo","doi":"10.1016/j.clinre.2025.102624","DOIUrl":"https://doi.org/10.1016/j.clinre.2025.102624","url":null,"abstract":"","PeriodicalId":10424,"journal":{"name":"Clinics and research in hepatology and gastroenterology","volume":" ","pages":"102624"},"PeriodicalIF":2.6,"publicationDate":"2025-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144141610","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A series of Sickle cell disease-associated inflammatory bowel diseases: high prevalence of colonic involvement and primary sclerosing cholangitis.","authors":"Julien Kirchgesner, Jeremy Augustin, Thomas Bazin, Pamela Freiha, Alexandre Nuzzo, Philippe Seksik, Iradj Sobhani, Pablo Bartolucci, Mathieu Uzzan","doi":"10.1016/j.clinre.2025.102615","DOIUrl":"https://doi.org/10.1016/j.clinre.2025.102615","url":null,"abstract":"<p><strong>Objective: </strong>Co-occurrence of Sickle Cell Disease (SCD) and Inflammatory Bowel Diseases (IBD) has been scarcely reported. Our aim was to explore the intersection between SCD and IBD, focusing on the impact of SCD on the natural course of IBD and drug safety.</p><p><strong>Methods: </strong>We conducted a multicenter retrospective case-control study including consecutive patients diagnosed with IBD and SCD. Each IBD patient with SCD was matched with up to 4 IBD patients without SCD. Matching criteria were IBD type, sex, date of birth, length of follow-up and year of diagnosis. The primary outcome was a complicated IBD course.</p><p><strong>Results: </strong>125 IBD patients were studied, including 24 SCD. 23/24 SCD patients had colonic involvement. 33.3% had concomitant primary sclerosing cholangitis (PSC) compared to 1% of controls (p<0.001). Survival without a complicated IBD course was estimated at 58.7% (CI95[49.6-69.5]) at 5 years for non-SCD patients, as compared to 63.3% (CI95[45.7-87.6]) for SCD patients SCD (p=0.36). The survival without the need of advanced therapy was estimated at 66.1% (CI95[57.3-76.2]) at 5 years for non-SCD patient, and at 78.2% (CI95[63-97.2]) in SCD patients (p=0.45) Regarding treatment safety, 26.3% of patients with SCD and 13.5% of controls experienced adverse events with biologics (p=0.17). There was one reported vaso-occlusive crisis associated with thiopurines.</p><p><strong>Conclusion: </strong>Patients with SCD and IBD displayed a distinctive phenotype with constant colonic involvement and high prevalence of PSC.</p>","PeriodicalId":10424,"journal":{"name":"Clinics and research in hepatology and gastroenterology","volume":" ","pages":"102615"},"PeriodicalIF":2.6,"publicationDate":"2025-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144141559","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Analgesics use and risk of pancreatitis: Result from the UK Biobank","authors":"Jiayi Wang ,&nbsp;Wanxin Long ,&nbsp;Zehong Qi ,&nbsp;Yangjie Liao ,&nbsp;Jingbo Li","doi":"10.1016/j.clinre.2025.102616","DOIUrl":"10.1016/j.clinre.2025.102616","url":null,"abstract":"<div><h3>Background</h3><div>Pancreatitis, an inflammatory pancreatic disorder, arises from various etiologies including alcohol, tobacco, and drug use. Although the initiation of pancreatitis has been strongly linked to several medications, the association between analgesic use and pancreatitis risk remains ambiguous in population-based studies.</div></div><div><h3>Methods</h3><div>This prospective cohort study involved 324,982 participants from the UK Biobank. Multivariable-adjusted Cox proportional hazards models were conducted to evaluate the longitudinal association between incident pancreatitis risk and analgesics use, encompassing opioids, non-steroidal anti-inflammatory drugs (NSAIDs), paracetamol, antimigraine preparations, and the mix. Subgroup and sensitivity analyses were conducted to assess the potential effects of baseline factors.</div></div><div><h3>Results</h3><div>Over a median follow-up of 13.70 years, 2303 cases of pancreatitis were identified. In the fully adjusted model, analgesics utilization increased the risk of pancreatitis (HR 1.13, 95 % CI 1.04–1.23), acute pancreatitis (AP) (HR 1.11, 95 % CI 1.01–1.22), and chronic pancreatitis (CP) (HR 1.25, 95 % CI 1.00–1.56) (All the above <em>p</em> &lt; 0.05). Furthermore, participants who used opioids presented the highest risk of pancreatitis (HR 1.85, 95 % CI 1.49–2.31, <em>p</em> &lt; 0.001), and the mixed group (HR 1.35, 95 % CI 1.21–1.51, <em>p</em> &lt; 0.001) followed. Compared to the non-analgesics group, the risk of both AP and CP also increased in the opioids and the mixed group. Subgroup analysis indicated that the impact of analgesics utilization on the pancreatitis risk may vary with certain covariates, such as age, cholelithiasis, etc. (p-interaction &lt;0.05).</div></div><div><h3>Conclusion</h3><div>In this large population-based prospective cohort, analgesics utilization, particularly opioids and mixed analgesics, was linked to an increased risk of pancreatitis.</div></div>","PeriodicalId":10424,"journal":{"name":"Clinics and research in hepatology and gastroenterology","volume":"49 7","pages":"Article 102616"},"PeriodicalIF":2.6,"publicationDate":"2025-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144126771","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Natalizumab-induced autoimmune liver injury","authors":"Jeanete Sharay Rodriguez-Martinez ,&nbsp;Nancy Haydee Serrano-Perez ,&nbsp;Guillermo Espinosa-Zarazua ,&nbsp;Jacqueline Cordova-Gallardo","doi":"10.1016/j.clinre.2025.102618","DOIUrl":"10.1016/j.clinre.2025.102618","url":null,"abstract":"","PeriodicalId":10424,"journal":{"name":"Clinics and research in hepatology and gastroenterology","volume":"49 7","pages":"Article 102618"},"PeriodicalIF":2.6,"publicationDate":"2025-05-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144119014","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Precision oncology in colorectal cancer: An anatomical revolution through molecular-clinical integration across colonic subsites","authors":"Jiefeng Zhao,&nbsp;Daxing Miao","doi":"10.1016/j.clinre.2025.102613","DOIUrl":"10.1016/j.clinre.2025.102613","url":null,"abstract":"<div><div>Colorectal cancer (CRC) exhibits significant heterogeneity across different colonic subsites, which vary in embryological origin, microbiome, metabolome, and molecular profiles, affecting tumorigenesis, treatment response, and prognosis. We emphasize the importance of this subsite heterogeneity to advance precision medicine in CRC.</div></div>","PeriodicalId":10424,"journal":{"name":"Clinics and research in hepatology and gastroenterology","volume":"49 6","pages":"Article 102613"},"PeriodicalIF":2.6,"publicationDate":"2025-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144070639","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A wandering spleen","authors":"Francesco Guerra,&nbsp;Francesco Matarazzo,&nbsp;Giuseppe Giuliani,&nbsp;Andrea Coratti","doi":"10.1016/j.clinre.2025.102614","DOIUrl":"10.1016/j.clinre.2025.102614","url":null,"abstract":"","PeriodicalId":10424,"journal":{"name":"Clinics and research in hepatology and gastroenterology","volume":"49 6","pages":"Article 102614"},"PeriodicalIF":2.6,"publicationDate":"2025-05-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144068425","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hepatocellular carcinoma risk in ICD-coded non-cirrhotic nonalcoholic fatty liver disease refined by fatty liver index: A nationwide South Korean cohort study","authors":"Chang Hun Lee ,&nbsp;Min Gu Kang ,&nbsp;Shinyoung Oh ,&nbsp;In Sun Gwak ,&nbsp;Chen Shen ,&nbsp;Ha Ram Oh ,&nbsp;Young Ran Park ,&nbsp;Jong Seung Kim ,&nbsp;Ji Hyun Park","doi":"10.1016/j.clinre.2025.102612","DOIUrl":"10.1016/j.clinre.2025.102612","url":null,"abstract":"<div><h3>Background/Aims</h3><div>Hepatocellular carcinoma (HCC) is an increasing global health burden, driven by demographic shifts and the growing prevalence of risk factors such as non-alcoholic fatty liver disease (NAFLD), now referred to as metabolic dysfunction-associated steatotic liver disease (MASLD). Despite the majority of NAFLD patients being in the non-cirrhotic stage, there is a notable lack of data on HCC incidence and risk factors, making it challenging to implement effective public health screening and prevention strategies.</div></div><div><h3>Methods</h3><div>This study conducted a longitudinal analysis of a nationwide cohort of NAFLD patients using big data from the National Health Insurance Service of South Korea to assess HCC incidence and risk factors, focusing on non-cirrhotic patients. NAFLD was identified through ICD-10 codes and refined using a fatty liver index (FLI) score above 30.</div></div><div><h3>Results</h3><div>A total of 529,811 patients were enrolled. After a washout period, 36,760 patients were newly diagnosed with NAFLD. The incidence rate of HCC per 100,000 person-years was 10.00 in healthy controls and 31.66 in NAFLD patients, further divided into 24.87 in non-cirrhotic NAFLD and 721.5 in cirrhotic NAFLD. In the 1:1 Propensity Score Matched analysis, HCC incidence in non-cirrhotic NAFLD was 24.89 per 100,000 person-years compared to 9.72 in matched healthy controls, yielding an adjusted hazard ratio (HR) of 2.69 (95 % CI 1.33–5.44). Multivariate Cox regression analysis indicated that both cirrhotic and non-cirrhotic NAFLD significantly increased the risk of developing HCC, with additional factors such as age, male sex, and type 2 diabetes. A subsequent analysis of non-cirrhotic NAFLD patients confirmed that advanced age and male sex remained significant risk factors for the development of HCC.</div></div><div><h3>Conclusions</h3><div>This study demonstrates that non-cirrhotic NAFLD patients, particularly males and those aged 70–79 years, have a significantly increased risk of HCC compared to healthy controls. Given the applicability of NAFLD concepts to MASLD, our findings could provide insights for identifying high-risk individuals within the MASLD spectrum and developing effective strategies to reduce the risk of HCC.</div></div>","PeriodicalId":10424,"journal":{"name":"Clinics and research in hepatology and gastroenterology","volume":"49 6","pages":"Article 102612"},"PeriodicalIF":2.6,"publicationDate":"2025-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143941814","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Circulating tumor DNA: A new tool to predict recurrence and guide treatment of colorectal cancer","authors":"Erwan Vo-Quang ,&nbsp;Annalice Gandini ,&nbsp;Valerie Taly ,&nbsp;Pierre Laurent-Puig ,&nbsp;Aziz Zaanan ,&nbsp;Julien Taieb","doi":"10.1016/j.clinre.2025.102611","DOIUrl":"10.1016/j.clinre.2025.102611","url":null,"abstract":"<div><div>Circulating tumor DNA (ctDNA) has emerged as a promising biomarker with diverse applications across different stages of colorectal cancer management. One of its primary roles is as a prognostic biomarker for detecting post-surgical molecular residual disease and predicting recurrence risk. Compared to traditional biomarkers and tissue biopsies, ctDNA provides a minimally invasive, dynamic, and comprehensive representation of tumor burden and molecular heterogeneity. However, challenges persist in standardizing ctDNA testing, improving sensitivity for early-stage disease, and ensuring widespread accessibility. In this review, we explore the biological characteristics of ctDNA, the methodologies for its detection, and its broad clinical applications in both localized and metastatic colorectal cancer.</div></div>","PeriodicalId":10424,"journal":{"name":"Clinics and research in hepatology and gastroenterology","volume":"49 7","pages":"Article 102611"},"PeriodicalIF":2.6,"publicationDate":"2025-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143971062","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of long-term changes in liver function and structure in patients exposed to SARS-CoV-2 infection: A prospective study","authors":"Erkin Saeed Saifi ,&nbsp;Francesco Faita ,&nbsp;Matteo Nardin ,&nbsp;Paola Orizio ,&nbsp;Alessandra Arrigoni ,&nbsp;Bianca Maria Roccon ,&nbsp;Beatrice Accordini ,&nbsp;Stefania Cecchinel ,&nbsp;Paolo Poisa ,&nbsp;Giovanni Pelizzari ,&nbsp;Anna Paini ,&nbsp;Massimo Salvetti","doi":"10.1016/j.clinre.2025.102606","DOIUrl":"10.1016/j.clinre.2025.102606","url":null,"abstract":"<div><h3>Background &amp; Aims</h3><div>Severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) binds to Angiotensin Converting Enzyme – 2 (ACE2) receptor targeting various organs including liver. Liver injury is a common feature of SARS-CoV-2 acute infection. A few studies have also described chronic hepatic alterations in patients with previous COVID-19. We hypothesize that steatosis seen in COVID-19 patients reflects their metabolic profile and is not caused by persistent inflammation sustained by SARS-CoV-2.</div></div><div><h3>Methods</h3><div>We conducted a prospective study to evaluate long-term changes in liver function and structure in patients hospitalized for COVID-19. Patients without a prior known hepatic disease with mild to moderate COVID-19 were enrolled during hospitalization and reevaluated during a follow-up visit at a medium 16 months. Complete blood panels with metabolic profile, BMI, alcohol consumption and physical activity were compared between baseline and follow-up. Specific ultrasound scans were obtained during hospital stay and at follow-up to quantify steatosis using Steatoscore2.0.</div></div><div><h3>Results</h3><div>Among 55 eligible patients, 33 were included in the analysis and only 3 (9 %) had a new diagnosis of steatosis at follow-up. Steatoscore2.0 did not change significantly from baseline to follow-up (1.7 vs 1.73, <em>p</em> = 0.348), while changes occurred in body mass index and physical activity estimated by IPAQ questionnaire (26.3 vs 26.6 kg/m², <em>p</em> = 0.005; 540 vs. 480, <em>p</em> = 0.015, respectively). There was a statistically significant increase in total cholesterol (144.5 vs 187.0 mg/dl, <em>p</em> = 0.003) and low-density lipoprotein-cholesterol (73.8 vs 113.9 mg/dl, <em>p</em> = 0.003). Inflammatory markers normalized at follow-up, including C-reactive protein (41.1 vs. 0.8 mg/L, <em>p</em> &lt; 0.001), and ferritin (410.0 vs. 91.0 ng/dl, <em>p</em> &lt; 0.001). Four patients had a 3-time rise in liver transaminase levels at baseline, and this was not confirmed at follow-up. Change in Steatoscore2.0 correlated significantly with Triglyceride-glucose index as a surrogate of insulin resistance.</div></div><div><h3>Conclusions</h3><div>In our study, long term functional and structural changes were not observed in patients with previous SARS-CoV-2 infection. There was a significant deterioration of metabolic profile post COVID-19</div></div>","PeriodicalId":10424,"journal":{"name":"Clinics and research in hepatology and gastroenterology","volume":"49 6","pages":"Article 102606"},"PeriodicalIF":2.6,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143927419","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluating the influence of maternal anti-HBs status on the antibody levels in vaccinated children","authors":"Naim Abu-Freha ,&nbsp;Safa Shibli ,&nbsp;Ohad Etzion ,&nbsp;Yaser Afianish ,&nbsp;Johnny Amer ,&nbsp;Heba Abu Kaf ,&nbsp;Nachum Zohar ,&nbsp;David Yardeni ,&nbsp;Rifaat Safadi","doi":"10.1016/j.clinre.2025.102608","DOIUrl":"10.1016/j.clinre.2025.102608","url":null,"abstract":"<div><div>Background and Aims: The mother's Hepatitis B Virus (HBV) vaccination status may impact the child's response. We aimed to investigate the children's vaccine response based on the mother's vaccination status. Methods: In a retrospective study, we included children ≤10 years old born to HBsAg negative mothers, with available maternal and children anti-HBs antibodies. Children of vaccinated and unvaccinated mothers were compared and categorized based on anti-HBs titers: 0–9.9, 10–100, 101–500, 501–1000, and ≥1001 mlU/ml. Results: 14,485 children were included. No significant difference in the anti-HBs positivity rate was found among the children of vaccinated and unvaccinated mothers (70.4 % vs. 69.7 %, <em>p</em> = 0.337). Vaccine response in vaccinated vs. unvaccinated mothers was 93.5 % vs. 92.1 % for the first year of age, 87.7 % vs. 87.3 % for age 3 years, and 82.5 % vs. 82.2 % for age 5 years, respectively. Young children (7–36 months) had higher protective titer rates than older children. A higher proportion of the ≥1001 mlU/ml category was recorded among children of mothers with negative or low anti-HBs antibodies in the first year of age, reaching 40.9 %. With age, the proportion of children with 10–100 mlU/ml increased, corresponding to the mother's titer. Conclusion: The maternal HBV vaccination status does not impact the children's response, but the mother's anti-HBs titers may affect the child's antibody level. Maternal anti-HBs antibody titers may neutralize the vaccine HBsAg to impair the reponse.</div></div>","PeriodicalId":10424,"journal":{"name":"Clinics and research in hepatology and gastroenterology","volume":"49 6","pages":"Article 102608"},"PeriodicalIF":2.6,"publicationDate":"2025-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143927420","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}